Remedy Plan Therapeutics Secures $18M to Advance Lead Asset into Phase 1/2 Trials

On May 13, 2025, Remedy Plan Therapeutics, a privately-owned pharmaceutical company specializing in innovative NAMPT inhibitors, announced the successful raising of over $18 million in a financing round that exceeded expectations. Key participants in this funding round include Schooner Capital and Alexandria Venture Investments. This recent injection of funds boosts the company's total funding to $55 million.

The primary objective of this capital infusion is to expedite the progression of RPT1G, a pioneering NAMPT inhibitor, into a Phase 1/2 clinical trial targeting patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). This advancement capitalizes on the ongoing first-in-human study with healthy volunteers, which is scheduled to conclude in May 2025. Additionally, the investment will fuel the continued development of Remedy Plan's portfolio of NAMPT inhibitors, which is expanding to address a range of conditions including solid tumors, autoimmune diseases, and obesity.

Dr. Greg Crimmins, Founder and CEO of Remedy Plan, expressed enthusiasm about the progress, stating, "For over 25 years, pharmaceutical companies have been attempting to exploit the NAMPT target, and we have finally succeeded. We are excited to move RPT1G into Phase 1/2 clinical trials for AML/MDS patients, who currently have limited treatment options. This funding not only propels us toward that objective but also enables the further development of our NAMPT inhibitor pipeline for other diseases."

NAMPT, an essential enzyme responsible for cellular energy management, is fundamental to human biology. Its dysregulation is implicated in over 20 diseases, establishing it as a valuable target for therapeutic development in biopharma. RPT1G, as the first NAMPT inhibitor to demonstrate tolerability without on-target toxicities, represents a significant breakthrough in overcoming challenges faced by previous NAMPT inhibitors.

Alexandra Manick, Principal at Schooner Capital, praised Remedy Plan's scientific approach, highlighting the potential of hyperbolic NAMPT inhibition. She remarked, "We are continuously impressed by Remedy Plan's distinct scientific strategy and believe the company is strategically positioned to create substantial value by addressing critical unmet needs in oncology, autoimmunity, and obesity with their unique NAMPT inhibitors."

Remedy Plan Therapeutics, as a clinical-stage pharmaceutical company, focuses on the development of hyperbolic NAMPT inhibitors. NAMPT, an enzyme integral to energy utilization in cells, plays a vital role in human biology. It is dysregulated across more than 20 diseases, including various cancers, autoimmune disorders, and metabolic conditions. Earlier attempts by other companies to inhibit NAMPT resulted in significant toxicities in healthy tissues, hindering clinical efficacy. Remedy Plan has pioneered a novel approach to NAMPT inhibition that maintains some NAMPT activity, thereby avoiding the toxicities seen in healthy tissues while effectively targeting diseased cells.

The company's leading asset, RPT1G, is engineered to retain biological function in healthy cells while inhibiting malignant cell activity. RPT1G is the first NAMPT inhibitor to be tested in healthy volunteers and is currently undergoing a Phase 1 clinical trial. A subsequent Phase 1/2 study involving AML and high-risk MDS patients, both alone and in combination with venetoclax, is slated to commence in the latter half of 2025.